Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) EBIAT (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of EBIAT readings, the most recent being $63.7 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 12.33% to $63.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $221.3 million, a 12.15% increase, with the full-year FY2025 number at $214.3 million, up 30.78% from a year prior.
  • EBIAT hit $63.7 million in Q1 2026 for Catalyst Pharmaceuticals, up from $52.7 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $63.7 million in Q1 2026 to a low of -$30.8 million in Q3 2023.
  • Median EBIAT over the past 5 years was $37.8 million (2023), compared with a mean of $35.1 million.
  • Biggest five-year swings in EBIAT: tumbled 235.24% in 2023 and later surged 242.65% in 2024.
  • Catalyst Pharmaceuticals' EBIAT stood at $25.5 million in 2022, then surged by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025, then grew by 20.94% to $63.7 million in 2026.
  • The last three reported values for EBIAT were $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025) per Business Quant data.